Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

2.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group.

N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.

3.

Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.

McLeay SC, Vis P, van Heeswijk RP, Green B.

Antimicrob Agents Chemother. 2014 Sep;58(9):5315-24. doi: 10.1128/AAC.01418-13. Epub 2014 Jun 23.

4.

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

van Heeswijk RP, Dannemann B, Hoetelmans RM.

J Antimicrob Chemother. 2014 Sep;69(9):2310-8. doi: 10.1093/jac/dku171. Epub 2014 May 23. Review.

PMID:
24860154
5.

The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.

Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM.

J Clin Pharmacol. 2014 Feb;54(2):133-40. doi: 10.1002/jcph.222. Epub 2013 Nov 23.

PMID:
24203510
6.

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Hoetelmans RM.

Int J Clin Pharmacol Ther. 2014 Feb;52(2):118-28. doi: 10.5414/CP201943.

PMID:
24161160
7.

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM.

J Clin Pharmacol. 2013 Aug;53(8):834-40. doi: 10.1002/jcph.107. Epub 2013 May 30.

PMID:
23720136
8.

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

Crauwels H, van Heeswijk RP, Stevens M, Buelens A, Vanveggel S, Boven K, Hoetelmans R.

AIDS Rev. 2013 Apr-Jun;15(2):87-101. Review.

PMID:
23681436
9.

Review of drug interactions with telaprevir and antiretrovirals.

van Heeswijk RP, Beumont M, Kauffman RS, Garg V.

Antivir Ther. 2013;18(4):553-60. doi: 10.3851/IMP2527. Epub 2013 Jan 23. Review.

PMID:
23344266
10.

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR, Focaccia R, Horban A, Pockros PJ, Van Heeswijk RP, De Meyer S, Luo D, Botfield M, Beumont M, Picchio G.

J Hepatol. 2013 May;58(5):883-9. doi: 10.1016/j.jhep.2012.12.023. Epub 2013 Jan 12.

PMID:
23321318
11.

Telaprevir: pharmacokinetics and drug interactions.

Garg V, Kauffman RS, Beaumont M, van Heeswijk RP.

Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7. Review.

PMID:
22954756
12.

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.

Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP.

Br J Clin Pharmacol. 2013 Feb;75(2):431-9. doi: 10.1111/j.1365-2125.2012.04345.x.

13.

Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.

Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V.

Antimicrob Agents Chemother. 2012 Jul;56(7):3641-7. doi: 10.1128/AAC.00077-12. Epub 2012 May 7.

14.

The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.

Sheehan NL, van Heeswijk RP, Foster BC, Akhtar H, Singhal N, Seguin I, DelBalso L, Bourbeau M, Chauhan BM, Boulassel MR, Burger DM, Lalonde RG, Cameron DW.

Molecules. 2012 Jan 12;17(1):688-702. doi: 10.3390/molecules17010688.

15.

Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.

Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP.

J Clin Pharmacol. 2012 Oct;52(10):1566-73. Epub 2011 Dec 12.

PMID:
22162542
16.

Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.

Diker B, Janneh O, van Heeswijk RP, Copeland KF.

Drug Metab Lett. 2010 Dec;4(4):241-5.

PMID:
20690898
17.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.

N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.

18.

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.

la Porte CJ, Li Y, Béïque L, Foster BC, Chauhan B, Garber GE, Cameron DW, van Heeswijk RP.

Clin Pharmacol Ther. 2007 Oct;82(4):389-95. Epub 2007 Mar 14.

PMID:
17361121
19.

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.

Cooper CL, van Heeswijk RP.

HIV Med. 2007 Jan;8(1):1-7. Review.

20.

Time-dependent interaction between lopinavir/ritonavir and fexofenadine.

van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW.

J Clin Pharmacol. 2006 Jul;46(7):758-67.

PMID:
16809801
21.

Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

Antoniou T, Tseng AL, van Heeswijk RP, Walker SE, Giguere P, Phillips EJ.

Ther Drug Monit. 2005 Dec;27(6):779-81.

PMID:
16306854
22.

Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity.

van Heeswijk RP, Cooper CL, Foster BC, Chauhan BM, Shirazi F, Seguin I, Phillips EJ, Mills E.

Pharmacotherapy. 2005 Dec;25(12):1725-8.

PMID:
16305291
23.

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Weaver JG, Tarze A, Moffat TC, Lebras M, Deniaud A, Brenner C, Bren GD, Morin MY, Phenix BN, Dong L, Jiang SX, Sim VL, Zurakowski B, Lallier J, Hardin H, Wettstein P, van Heeswijk RP, Douen A, Kroemer RT, Hou ST, Bennett SA, Lynch DH, Kroemer G, Badley AD.

J Clin Invest. 2005 Jul;115(7):1828-38.

24.

Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW.

Br J Clin Pharmacol. 2005 Apr;59(4):398-404.

25.

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW.

Clin Pharmacol Ther. 2004 Dec;76(6):588-97.

PMID:
15592330
26.

Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.

van Heeswijk RP.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):75-81. Review.

PMID:
15482103
27.

Evaluation of HIV drug interaction web sites.

Sheehan NL, Kelly DV, Tseng AL, van Heeswijk RP, Béïque LC, Hughes CA; Canadian HIV/AIDS Pharmacists Network.

Ann Pharmacother. 2003 Nov;37(11):1577-86.

PMID:
14565802
28.

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.

Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M Jr, van Heeswijk RP, Lange JM, Cooper DA, Phanuphak P, Burger DM.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):134-9.

PMID:
14526202
29.

A review of low-dose ritonavir in protease inhibitor combination therapy.

Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW.

Clin Infect Dis. 2003 Jun 15;36(12):1585-92. Epub 2003 Jun 5. Review.

PMID:
12802760
30.

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):375-9.

PMID:
12640194
31.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
32.

Critical issues in therapeutic drug monitoring of antiretroviral drugs.

Van Heeswijk RP.

Ther Drug Monit. 2002 Jun;24(3):323-31. Review.

PMID:
12021621
33.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
34.

Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

Rongkavilit C, van Heeswijk RP, Limpongsanurak S, Thaithumyanon P, Boonrod C, Hassink EA, Srigritsanapol A, Chuenyam T, Ubolyam S, Hoetelmans RM, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):455-63.

PMID:
11981361
35.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

Antivir Ther. 2001 Dec;6(4):201-29. Review.

PMID:
11878403
36.

Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.

van Heeswijk RP, Cohen Stuart JW, Burger DM, Beijnen JH, Borleffs JC, Hoetelmans RM; CHEESE Study Group.

Br J Clin Pharmacol. 2002 Feb;53(2):211-2. No abstract available.

37.

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

van Praag RM, van Weert EC, van Heeswijk RP, Zhou XJ, Sommadossi JP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM.

Antimicrob Agents Chemother. 2002 Mar;46(3):896-9.

38.

Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.

Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Hoetelmans RM, Lange JM, Beijnen JH.

Ther Drug Monit. 2001 Dec;23(6):606-11.

PMID:
11802091
39.

Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

van Praag RM, van Heeswijk RP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM.

Clin Infect Dis. 2001 Oct 15;33(8):e91-2. Epub 2001 Sep 20.

PMID:
11565093
40.

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):344-9.

PMID:
11468422
41.

Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Beijnen JH, Lange JM, Hoetelmans RM.

Ther Drug Monit. 2001 Jun;23(3):255-8.

PMID:
11360034
42.

Nevirapine plus didanosine: once or twice daily combination?

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Reiss P, Lange JM, Kwakkelstein MO, Beijnen JH, Hoetelmans RM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):93-5. No abstract available.

PMID:
11064511
43.

Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.

Taylor S, van Heeswijk RP, Hoetelmans RM, Workman J, Drake SM, White DJ, Pillay D.

AIDS. 2000 Sep 8;14(13):1979-84.

PMID:
10997403
44.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
45.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
46.
47.

Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir.

Koks CH, van Heeswijk RP, Veldkamp AI, Meenhorst PL, Mulder JW, van der Meer JT, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jan 7;14(1):89-90. No abstract available.

PMID:
10714572
48.

Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

Veldkamp AI, van Heeswijk RP, Meenhorst PL, Mulder JW, Lange JM, Beijnen JH, Hoetelmans RM.

J Chromatogr B Biomed Sci Appl. 1999 Oct 29;734(1):55-61.

PMID:
10574190
49.

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Hoetelmans RM, Mulder JW, Schreij G, Hsu A, Lange JM, Beijnen JH, Meenhorst PL.

AIDS. 1999 Oct 1;13(14):F95-9.

PMID:
10513637
50.

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.

Veldkamp AI, van Heeswijk RP, Hoetelmans RM, Meenhorst PL, Mulder JW, Lange JM, Beijnen JH.

J Chromatogr B Biomed Sci Appl. 1999 Apr 30;727(1-2):151-7.

PMID:
10360434

Supplemental Content

Loading ...
Support Center